Orphazyme
969.9 DKK +6.52%Be the first to follow this company
Orphazyme operates in biochemistry. The company specializes in research and development of unusual diseases where there is a deficiency in the function of heat coke proteins. The technique is based on arimoclomol, which stimulates the production of heat coke proteins in cells that experience increased degrees of stress and toxicity. Diseases that the company's products aim to treat include Gaucher's disease and amyotrophic lateral sclerosis (ALS). The company is headquartered in Copenhagen.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ORPHA
Daily low / high price
949.9 / 970
DKK
Market cap
34.25M DKK
Turnover
49.68K DKK
Volume
52
Financial calendar
Interim report
20.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
LSP V Coöperatieve U.A. | 7.8 % | 7.8 % |
Sunstone Life Science Ventures Fund II K/S | 5.2 % | 5.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Forlig af udestående samt ændring af guidance:
Udstedelse af RSU program
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools